Osaic Holdings Inc. Raises Stock Holdings in Sanofi $SNY

Osaic Holdings Inc. boosted its holdings in Sanofi (NASDAQ:SNY) by 17.0% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 188,526 shares of the company’s stock after purchasing an additional 27,427 shares during the period. Osaic Holdings Inc.’s holdings in Sanofi were worth $9,189,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the business. Capital Analysts LLC raised its stake in shares of Sanofi by 14.0% during the 1st quarter. Capital Analysts LLC now owns 1,664 shares of the company’s stock worth $92,000 after purchasing an additional 204 shares during the period. Thomasville National Bank raised its position in Sanofi by 0.3% in the second quarter. Thomasville National Bank now owns 80,440 shares of the company’s stock worth $3,886,000 after acquiring an additional 211 shares during the period. CreativeOne Wealth LLC boosted its stake in Sanofi by 2.8% in the second quarter. CreativeOne Wealth LLC now owns 8,980 shares of the company’s stock valued at $434,000 after acquiring an additional 241 shares during the last quarter. U.S. Capital Wealth Advisors LLC grew its position in shares of Sanofi by 4.1% during the 2nd quarter. U.S. Capital Wealth Advisors LLC now owns 6,227 shares of the company’s stock valued at $301,000 after acquiring an additional 247 shares during the period. Finally, Whipplewood Advisors LLC grew its position in shares of Sanofi by 18.2% during the 2nd quarter. Whipplewood Advisors LLC now owns 1,606 shares of the company’s stock valued at $78,000 after acquiring an additional 247 shares during the period. Institutional investors own 14.03% of the company’s stock.

Sanofi Stock Performance

Shares of SNY opened at $48.18 on Friday. Sanofi has a 52-week low of $44.62 and a 52-week high of $60.12. The stock’s 50-day simple moving average is $49.77 and its 200 day simple moving average is $48.96. The company has a debt-to-equity ratio of 0.16, a quick ratio of 0.30 and a current ratio of 1.06. The stock has a market capitalization of $118.31 billion, a price-to-earnings ratio of 11.28, a price-to-earnings-growth ratio of 1.31 and a beta of 0.44.

Sanofi (NASDAQ:SNY) last posted its earnings results on Friday, October 24th. The company reported $2.91 earnings per share for the quarter, beating analysts’ consensus estimates of $1.60 by $1.31. Sanofi had a return on equity of 12.70% and a net margin of 21.96%.The business had revenue of $15.46 billion during the quarter, compared to analyst estimates of $12.62 billion. During the same quarter in the previous year, the firm earned $2.25 EPS. The company’s quarterly revenue was down 7.5% compared to the same quarter last year. Research analysts forecast that Sanofi will post 4.36 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently commented on SNY. Jefferies Financial Group reaffirmed a “buy” rating on shares of Sanofi in a report on Monday, October 27th. Weiss Ratings reiterated a “hold (c)” rating on shares of Sanofi in a research note on Monday, December 15th. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Sanofi in a report on Monday, December 8th. HSBC reaffirmed a “buy” rating on shares of Sanofi in a report on Wednesday, December 10th. Finally, Morgan Stanley upgraded shares of Sanofi from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $56.00 to $58.00 in a research note on Monday, September 8th. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $62.67.

Sanofi Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.